Methylprednisolone hemisuccinate

Generic Name: Methylprednisolone hemisuccinate

Brand Names: Solu-medrol

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄O_₈

CAS Number: 2921-57-5

Unique Ingredient Identifier: 5GMR90S4KN

Background: A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Associated Conditions: Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis

Associated Therapies: Palliative Treatment

Clinical Trials

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

Phase 3

Not yet recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: BGB-16673
Drug: Bendamustine
Drug: Rituximab
Drug: Methylprednisolone

First Posted Date: 2025-05-14

Last Posted Date: 2025-05-20

Lead Sponsor: BeiGene

Target Recruit Count: 150

Registration Number: NCT06970743

Comparison of the Effectiveness of Oral and Intratympanic Corticosteroid Treatments in Patients Diagnosed With Sudden Sensorineural Hearing Loss

Phase 4

Recruiting

Conditions: Sudden Sensorineural Hearing Loss

Interventions: Drug: Methylprednisolone (drug)
Drug: Dexamethasone

First Posted Date: 2025-05-13

Last Posted Date: 2025-05-13

Lead Sponsor: Dr. Lutfi Kirdar Kartal Training and Research Hospital

Target Recruit Count: 214

Registration Number: NCT06968507

Locations: 🇹🇷
Dr Lütfi Kırdar City Hospital, İstanbul, Kartal, Turkey

MAGIC Ruxolitinib for aGVHD

Phase 2

Recruiting

Conditions: Acute Graft-versus-host Disease
Allogeneic Bone Marrow Transplantation
Adverse Effects

Interventions: Drug: Ruxolitinib
Drug: Methylprednisolone

First Posted Date: 2025-04-20

Last Posted Date: 2025-05-14

Lead Sponsor: John Levine

Target Recruit Count: 98

Registration Number: NCT06936566

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 4 locations

Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia

Not Applicable

Not yet recruiting

Conditions: Drug Induced Liver Injury

Interventions: Drug: Methylprednisolone
Drug: Magnesium isoglycyrrhizinate
Drug: Glutathione
Drug: Silymarin
Drug: Polyene Phosphatidylcholine
Drug: Ursodeoxycholic acid capsules
Drug: Ademetionine 1,4-Butanedisulfonate
Procedure: Plaslna exchange
Procedure: Liver transplantation

First Posted Date: 2025-04-10

Last Posted Date: 2025-04-10

Lead Sponsor: General Hospital of Shenyang Military Region

Target Recruit Count: 232

Registration Number: NCT06922669

Locations: 🇨🇳
Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area), Shenyang, Liaoning, China